Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas

A majority of patients with a V600x melanoma respond quickly to BRAF/MEK inhibition (BRAFi/MEKi) and have an obvious clinical benefit. Nearly all the patients after this initial phase will develop resistance. Therefore, non-invasive early markers of response/non-response are needed in order to ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Acciardo, Stefania, Mignion, Lionel, Joudiou, Nicolas, Bouzin, Caroline, Baurain, Jean-François, Gallez, Bernard, Jordan, Bénédicte F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908289/
https://www.ncbi.nlm.nih.gov/pubmed/29682188
http://dx.doi.org/10.18632/oncotarget.24709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5908289/
https://www.ncbi.nlm.nih.gov/pubmed/29682188
http://dx.doi.org/10.18632/oncotarget.24709

Ejemplares similares